This fraction significantly exceeds the 31% of contacts to CTCF binding sites and 18% of contacts to DLBCL SEs being restored after the A-485 treatment (P < 0.001, Fig. S15B). This evidence concerns the gene CTCF and diffuse large B-cell lymphoma.